Brooks Laboratories Limited (IN:BROOKS)

:BROOKS

BROOKS

Brooks Laboratories Limited

RESEARCH TOOLSreports

Want to see IN:BROOKS full AI Analyst Report?

Brooks Laboratories Limited (BROOKS) Price & Analysis

2 Followers

BROOKS Stock Chart & Stats

₹123.65

-₹3.80(-2.00%)

At close: Jan 09 4:00 PM EST

₹123.65

-₹3.80(-2.00%)

Day’s Range― - ―

52-Week Range₹36.50 - ₹165.95

Previous CloseN/A

Volume3.81K

Average Volume (3M)2.20K

Market Cap

₹1.92B

Enterprise Value₹2.00B

Total Cash (Recent Filing)₹18.03M

Total Debt (Recent Filing)₹78.33M

Price to Earnings (P/E)7.9

Beta1.67

Next Earnings

Aug 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.97

Shares Outstanding29,457,249

10 Day Avg. Volume1,280

30 Day Avg. Volume2,199

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.89

Price to Sales (P/S)1.27

P/FCF Ratio21.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance-sheet ConservatismVery low leverage (debt-to-equity ~0.07) provides durable financial flexibility: it reduces refinancing risk, preserves capacity for R&D or capex, and allows management to absorb shocks or pursue opportunistic investments without compromising solvency over the next several quarters.

Profitability ReboundA substantial swing to positive net margins (~29%) and ~20% ROE indicates the company has restored core earnings power. If sustained, this generates internal funding for growth and signals improved unit economics and pricing or cost control that can persist beyond short-term cycles.

Improving Cash GenerationThe move to positive operating and free cash flow marks a structural recovery in cash generation versus multi-year outflows. Consistent positive FCF enhances self-funding ability, reduces reliance on external capital, and supports longer-term investments or shareholder returns if conversion stabilizes.

Bears Say

Top-line ContractionA ~23% revenue decline materially weakens scale economics and questions sustainability of the margin rebound. Persistent top-line erosion limits pricing power, reduces R&D and commercial leverage, and makes earnings improvements harder to sustain without a credible revenue recovery plan.

Weak Cash ConversionOperating cash covers under 50% of reported income, indicating earnings quality gaps. Continued weak conversion leaves the business exposed to working-capital swings, constrains reinvestment capacity, and means accounting profits may not translate reliably into durable free cash flow.

Earnings Volatility & Prior LossesHistoric margin volatility and recent multi-year losses increase execution risk: management must consistently deliver stable demand and cost control to avoid relapse. This structural uncertainty complicates planning, makes capital allocation riskier, and raises the bar for sustained recovery.

Brooks Laboratories Limited News

Brooks Laboratories Announces Strategic Merger of Joint Venture

Brooks Laboratories Limited ( ($IN:BROOKS) ) has shared an announcement. Brooks Laboratories Limited has announced a merger by...

9M ago

BROOKS FAQ

What was Brooks Laboratories Limited’s price range in the past 12 months?

Brooks Laboratories Limited lowest stock price was ₹36.50 and its highest was ₹165.95 in the past 12 months.

What is Brooks Laboratories Limited’s market cap?

Brooks Laboratories Limited’s market cap is ₹1.92B.

When is Brooks Laboratories Limited’s upcoming earnings report date?

Brooks Laboratories Limited’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.

How were Brooks Laboratories Limited’s earnings last quarter?

Brooks Laboratories Limited released its earnings results on May 29, 2026. The company reported ₹0.52 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.52.

Is Brooks Laboratories Limited overvalued?

According to Wall Street analysts Brooks Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brooks Laboratories Limited pay dividends?

Brooks Laboratories Limited does not currently pay dividends.

What is Brooks Laboratories Limited’s EPS estimate?

Brooks Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brooks Laboratories Limited have?

Brooks Laboratories Limited has 29,457,249 shares outstanding.

What happened to Brooks Laboratories Limited’s price movement after its last earnings report?

Brooks Laboratories Limited reported an EPS of ₹0.52 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 4.998%.

Which hedge fund is a major shareholder of Brooks Laboratories Limited?

Currently, no hedge funds are holding shares in IN:BROOKS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brooks Laboratories Limited

Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product portfolio includes carbapenem medications, various tablets, dry syrups, both liquid and powdered injectable solutions, and specialized eye and ear drops. Brooks Laboratories Limited was established in 2002 and is headquartered in Mumbai, India.